Helus Pharma shareholders approve name change from Cybin Inc.

Helus Pharma shareholders approved the company’s legal name change from Cybin Inc. to Helus Pharma Inc. with 99.32% support; the change takes effect October 1, 2026. Investors also approved Zeifmans LLP as auditor (99.21%), set the board at eight directors (99.33%), and elected all eight nominees, though four directors received roughly 71.3%-71.6% support. The clinical-stage company continues Phase 3 development of HLP003 for major depressive disorder and Phase 2 development of HLP004 for generalized anxiety disorder.

Analysis

This is administratively neutral and should not alter HELP’s probability-weighted valuation absent a concurrent filing that changes capitalization, cash runway, trial timelines, or strategic alternatives. A legal-name transition can create temporary retail and database-symbol friction around the effective date, but it is not a clinical or commercial catalyst; any sustained move attributed to the meeting should be treated skeptically.

The investable issue remains HLP003’s Phase 3 execution: for a clinical-stage CNS issuer, the stock is likely dominated by enrollment pace, endpoint design, placebo-adjusted efficacy, safety/tolerability, and financing needs rather than governance outcomes. The relatively lower support for several director nominees is not independently actionable, but it raises a watch item: investors should review insider ownership, related-party arrangements, and whether the board has sufficient trial-commercialization expertise before assigning governance quality a premium.

Over the next 1-3 months, monitor clinical-trial registry updates, cash burn, and any equity-at-the-market activity; financing announcements can overwhelm otherwise positive pipeline messaging. Over 6-18 months, successful differentiation versus existing antidepressants and other psychedelic-inspired/CNS programs matters more than headline efficacy alone—durable value requires a tolerability, onset-of-action, or treatment-resistant-population advantage that supports payer adoption. The contrarian view is that a name change may be interpreted as a strategic reset, but without measurable clinical de-risking it should not justify multiple expansion.

Key Decisions for Investors

• No directional position solely on the shareholder-meeting outcome; classify HELP as an event-driven watchlist name rather than a governance catalyst trade.
• Before considering a long, require verification of cash runway through the next material HLP003 data milestone, including quarterly operating cash burn and any available ATM/shelf capacity; a financing need inside 12 months is thesis-negative.
• Set alerts for HLP003 enrollment completion, protocol amendments, FDA interactions, and top-line-data guidance. Initiate only after a timeline-confirming disclosure or material clinical update, with position sizing consistent with binary Phase 3 risk.
• If HELP rallies materially into the October 2026 legal-name effective date without new clinical data or funding clarity, consider reducing exposure or a tactical short only where borrow and liquidity permit; the falsifier is a concurrent trial, partnership, or balance-sheet catalyst.